Subject to regulatory rules and laws that differ in the public and private sectors, PBMs carry out what plan sponsors direct them to in terms of the products they actually cover for enrollees
Regular monitoring helps make sure youre tolerating the medication well
Many studies only report superficial phenotypic changes, such as Th17/Treg ratios or related cytokines, which greatly reduces the comparability and reproducibility of the research
Some or all of the lower repeat-overdose risk could reflect those kinds of differences rather than the medication itself
When shes not testing the next big thing, youll find her perfecting tequila cocktail recipes, listening to female-focused financial podcasts or trying to master the art of meditation.
However, with the FDA declaring the shortages of tirzepatide and semaglutide resolved in late 2024 and early 2025 2 , the regulatory shield has evaporated